The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
BACKGROUND
Decision-making regarding adjuvant chemotherapy for early-stage breast cancer can be guided by genomic assays such as OncotypeDX. The concordance of expected clinical decisions guided by OncotypeDX and prognostication online tools such as PREDICT is unknown.


METHODS
We performed a retrospective single-center cohort study comprising all women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, node negative disease, whose tumors were sent for OncotypeDX analysis. Expected decision on adjuvant chemotherapy was evaluated using OncotypeDX and using PREDICT. The concordance between these two tools was calculated. The impact on concordance of prespecified features was assessed, including age, tumor size, intensity of ER and progesterone receptor (PR), grade, Ki67 and perineural and lymphovascular invasion.


RESULTS
A total of 445 women were included. Overall concordance was 75% (K = 0.284). The concordance was significantly higher for grade 1 disease compared to grade 2-3 (93% vs 72%, P < .001), tumor ≤ 1 cm compared to >1 cm (85% vs 72%, P = .009), PR positive compared to PR negative (78% vs 58%, P < .001) and ki67 < 10% compared to ≥10% (92% vs 63%, P < .001). The intensity of ER and the presence of perineural or lymphovascular invasion had no significant impact on concordance.


CONCLUSIONS
Compared to PREDICT, using OncotypeDx in node negative, ER positive disease is expected to change the clinical decision in a quarter of patients. The concordance between OncotypeDx and PREDICT is influenced by pathological features. In patients with very low risk, treatment decisions may be made based solely on clinical risk assessment.
['Goldstein|Daniel A|DA|0000-0002-8082-9622', 'Mayer|Chen|C|', 'Shochat|Tzippy|T|', 'Reinhorn|Daniel|D|', 'Moore|Assaf|A|0000-0002-1502-3729', 'Sarfaty|Michal|M|', 'Yerushalmi|Rinat|R|', 'Goldvaser|Hadar|H|0000-0002-9557-4634']
D000328:Adult D000367:Age Factors D000368:Aged D000369:Aged, 80 and over D001943:Breast Neoplasms D017024:Chemotherapy, Adjuvant D000066491:Clinical Decision-Making D015331:Cohort Studies D005260:Female D020869:Gene Expression Profiling D005820:Genetic Testing D023281:Genomics D006801:Humans D008875:Middle Aged D060787:Neoplasm Grading D009361:Neoplasm Invasiveness D011379:Prognosis D018719:Receptor, ErbB-2 D011960:Receptors, Estrogen D011980:Receptors, Progesterone D012189:Retrospective Studies D047368:Tumor Burden
predict tool breast cancer adjuvant genomic assays oncotype